INDIAN-IMMIGRATION
8.6.2022 10:02:10 CEST | Business Wire | Press release
India has recently become a popular tourist destination for travelers thanks to the breathtaking sceneries it has to offer. Besides adventure travel and cultural tours, wellness tourism in India has emerged as a significant and rapidly expanding tourism segment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005070/en/
The growth of wellness tourism in India
In 2020, India ranked 12th in the top 20 largest wellness tourism markets in the world, with more than 48.2 million wellness trips. Making use of this travelers' interest, India offers plenty of wellness retreats and resorts for tourists as well as advantageous conditions to get Indian visas.
Many travelers may be confused about the difference between wellness tourism and medical tourism . Medical tourism is about traveling to a different place for specific medical treatments while wellness tourism is associated with the pursuit of maintaining or enhancing travelers’ wellbeing.
Especially, more people are choosing health and wellness tourism in India to recharge their batteries and refresh themselves post pandemic.
Lauren Jane, an American traveler who had a wellness vacation in Ananda in the Himalayas Resort, India, says: “The activities here help me re-balance and relieve stress after the pandemic, while the healthy organic cuisine maintains my health during the trip. I will come back to experience more wellness tourism destinations in India.”
Typical types of wellness tourism in India and corresponding entry documents
India focuses on promoting wellness tourism in 03 key sectors: Meditation, yoga, and massage therapies.
One of the most popular activities on a wellness trip in India is meditation. Travelers will participate in meditation activities in a natural space of plants, water, and clouds. Meditation is a good way for tourists to reset their bodies, and enjoy the moments of relaxation in their souls.
Known as the birthplace of yoga, India promotes the construction of wellness retreats suitable for yoga practices. Most of the retreats are settled close to nature, surrounded by the lush green forests, providing tourists with quiet spaces for doing yoga.
Ayurvedic massage is unique in many wellness retreats in India, bringing relaxing and soothing experiences for tourists. This massage therapy uses oils, herbs, and natural products to help tourists relieve emotional stress, rejuvenate their mind and soul.
“To experience wellness tours in India, travelers just need to prepare a valid passport to apply for an Indian visa, ” said Mrs. Kim, Relationship Manager in Indian Immigration Services.
Useful tips for tourists from Indian Immigration Service Experts
For a pleasant trip to India, travelers should get a visa beforehand. “To choose a reliable partner for making an eVisa, travelers need to consider factors including the fees, processing time, and professionalism of the staff,” Mrs. Kim also said.
Instead of visiting the embassy to apply for a India visa, foreign travelers can obtain an eVisa on the Indian Immigration Services website. As an applicant, travelers need to meet the visa requirements to be granted an Indian eVisa for tourists.
India Immigration Services makes it easier for travelers to apply for an Indian visa online with reasonable Indian eVisa fees. We assisted more than 25,000 customers globally in making eVisas to India. In addition, we also offer Travel Insurance in order to help our customers cover the cost of medical treatments during the trip.
No more complicated process to get a Visa to enter India, travelers now can expect to have a memorable wellness trip in this fascinating country with India Immigration Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005070/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom